HALO Halozyme Therapeutics Forecast, Technical & Fundamental Analysis

HALO in +1.51% Uptrend, growing for three consecutive days on November 13, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where HALO advanced for three days, in of 322 cases, the price rose further within the following month. The odds of a continued upward trend are .

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 04, 2025. You may want to consider a long position or call options on HALO as a result. In of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for HALO just turned positive on October 24, 2025. Looking at past instances where HALO's MACD turned positive, the stock continued to rise in of 39 cases over the following month. The odds of a continued upward trend are .

HALO moved above its 50-day moving average on November 12, 2025 date and that indicates a change from a downward trend to an upward trend.

The Aroon Indicator entered an Uptrend today. In of 303 cases where HALO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

The 10-day moving average for HALO crossed bearishly below the 50-day moving average on October 09, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HALO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

HALO broke above its upper Bollinger Band on November 11, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HALO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (16.611) is normal, around the industry mean (24.460). P/E Ratio (15.019) is within average values for comparable stocks, (62.829). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.004). Dividend Yield (0.000) settles around the average of (0.046) among similar stocks. P/S Ratio (7.194) is also within normal values, averaging (339.020).